NEW YORK, Jan. 30, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of BioClinica Inc. ("BioClinica" or the "Company") (NASDAQ: BIOC) (ISIN: US09071B1008) (CUSIP: 09071B100) concerning the proposed acquisition of BioClinica by JLL Partners, Inc. in a transaction valued at approximately $123 million in cash.
The investigation concerns whether the BioClinica directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, BioClinica shareholders will be entitled to receive $7.25 per share in cash for each share of BioClinica common stock. However, the price to EBITDA and revenue multiples are below those of comparable transactions' averages. Moreover, at least one analyst has set a target price of $9 per share.
BioClinica shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at email@example.com or 212-661-1100 or 888-476-6529, ext. 237.
The firm is also investigating actions on behalf of shareholders for the following companies: Arbitron Inc., Net1 Ueps Technologies, Inc., Universal Technical Institute, Clearwire Corporation, Ameristar Casinos, Inc. K-Swiss, Inc., Neptune Technologies Bioressources, Inc., Copano Energy LLC., and Somerset Hills Bancorp.
The Pomerantz Firm, with offices in New York, Chicago and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP